Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

RUNNING HEAD

MRD assessment by sequencing in multiple myeloma

AUTHORS AND AFFILIATIONS

Joaquin Martinez-Lopez¹, Juan J. Lahuerta¹, François Pepin², Marcos González³, Santiago Barrio¹, Rosa Ayala¹, Noemí Puig³, María A. Montalban¹, Bruno Paiva⁴, Li Weng², Cristina Jiménez³, María Sopena¹, Martin Moorhead², Teresa Cedena¹, Immaculada Rapado¹, María Victoria Mateos³, Laura Rosiñol⁵, Albert Oriol⁶, María J. Blanchard⁷, Rafael Martínez⁸, Joan Bladé⁵, Jesús San Miguel⁴, Malek Faham², and Ramón García-Sanz³

¹Hospital Universitario 12 de Octubre, Madrid; ²Sequenta, Inc., South San Francisco, United States; ³Hospital Universitario de Salamanca-IBSAL, IBMCC-CSIC, Salamanca, Spain; ⁴Clínica Universitaria de Navarra, Centro de Investigación Médica Aplicada (CIMA); ⁵Hospital Clínic i Provincial de Barcelona, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; ⁶Hospital Germans Trias i Pujol; ⁷Hospital Ramón y Cajal; ⁸Hospital Clínico de Madrid
CORRESPONDING AUTHOR
Joaquin Martinez-Lopez
Hematología Hospital 12 de Octubre
Universidad Complutense
Edificio Atención Ambulatoria. Planta Sexta Bloque D
Avenida de Córdoba s/n. Madrid. 28041. Spain
Email: jmartinezlo@hematologia12octubre.com
Phone: +34917792787
Fax: +34913908000

SCIENTIFIC CATEGORY
Lymphoid neoplasia

KEYWORDS
Sequencing, minimal residual disease, multiple myeloma
KEY POINTS

- MRD assessment by sequencing is prognostic of time to tumor progression (TTP) and overall survival (OS) in multiple myeloma patients.

- Among patients in CR, MRD assessment by sequencing enables identification of two distinct subgroups with different TTP.
ABSTRACT

We assessed the prognostic value of minimal residual disease (MRD) detection in multiple myeloma (MM) patients using a sequencing-based platform in bone marrow samples from 133 MM patients in at least very good partial response (VGPR) following front-line therapy. Deep sequencing was carried out in patients in which a high-frequency myeloma clone was identified and MRD was assessed using the IGH-VDJH, IGH-DJH and IGK assays. The results were contrasted with those of multiparametric flow cytometry (MFC) and ASO-PCR. The applicability of deep sequencing was 91%. Concordance between sequencing and MFC and ASO-PCR was 83% and 85%, respectively. Patients who were MRD- by sequencing had a significantly longer time to tumor progression (TTP) (median 80 vs. 31 months; \( P < 0.0001 \)) and overall survival (median not reached vs. 81 months; \( P = 0.02 \)), compared with patients who were MRD+. When stratifying patients by different levels of MRD, the respective TTP medians were: MRD \( \geq 10^{-3} \) 27 months, MRD \( 10^{-3} \) to \( 10^{-5} \) 48 months, and MRD \( < 10^{-5} \) 80 months (\( P \) from 0.003 to 0.0001). 92% of VGPR patients were MRD+. In CR patients, the TTP remained significantly longer for MRD- compared to MRD+ patients (131 vs. 35 months; \( P = 0.0009 \)).
INTRODUCTION

Historically, the goal of multiple myeloma (MM) therapy has been to achieve a partial response or disease stabilization.\(^1,2\) The introduction of novel agents, including thalidomide, lenalidomide and bortezomib, in combination with autologous stem cell transplantation, has dramatically altered the treatment paradigm and significantly improved overall survival (OS) in MM patients.\(^3\) As a result, increasing emphasis has been placed on the achievement of complete response (CR), which is defined as the absence of M-protein by immunofixation and less than 5% plasma cells (PCs) in bone marrow (BM).\(^4,5\) Unfortunately, most patients with MM ultimately relapse and die of the disease despite achieving CR.\(^6\) Although some reports have attribute the sustainability of MM has been suspected to a minor population of clonogenic CD138\(^-\) cells, the dominant population of CD138\(^+\) PCs contain clonogenic cells\(^7\). Therefore, most but not all of MM relapses can be attributed to the persistence of undetectable minimal residual disease (MRD). Thus a CR definition that is based solely on protein analysis and conventional cytological cell morphology techniques is insufficient.

The identification of MRD is an emerging component of CR assessment in MM patients. Similar to some lymphoid\(^8\) or myeloid\(^9\) malignancies, traditional methods for measuring MRD in MM include Allele Specific Polymerase Chain Reaction (ASO-PCR) of rearranged B-cell receptor genes and multiparametric flow cytometry (MFC). Such methods are based on the identification of clonotypic sequences or aberrant immunophenotypes, respectively. Previous studies have shown that molecular and MFC remissions are associated with significantly longer progression free survival (PFS) and OS in MM patients.\(^10,11\) Moreover, such studies have demonstrated that in patients who achieved conventional CR, those who demonstrated a complete clearance of bone marrow tumor cells assessed by PCR or MFC have a significantly
longer PFS and OS compared to those with persistent tumor cells. This suggests that molecular or immunophenotypic remissions are more sensitive than conventional CR by immunofixation.

However, both techniques have some disadvantages. ASO-PCR in MM is associated with high technical complexity and low applicability\textsuperscript{12}. Although some alternative PCR strategies for assessing MRD in MM could improve the applicability\textsuperscript{13-16}, they typically result in decreased sensitivity. MFC has a higher applicability, virtually covering all patients\textsuperscript{17} and the current sensitivity ranges between 10\textsuperscript{-4} and 10\textsuperscript{-5}; however, further standardization efforts are required. Moreover, no tumor cells are detectable by MFC or PCR in a fraction of patients who ultimately relapse, which indicates there is room for improvement in the MRD detection limit and suggests that alternative techniques should be investigated.

Recent reports have demonstrated the utility of high-throughput sequencing-based MRD assessment in lymphoid malignancies\textsuperscript{18-22}. This quantitative method, termed the LymphoSIGHT\textsuperscript{TM} platform, relies on amplification and sequencing of immunoglobulin gene segments using consensus primers, with a demonstrated applicability higher than 90%. Standardized algorithms quantify the number of cancer molecules with an assay sensitivity at or below 10\textsuperscript{-6} which represents at least 1 log greater sensitivity than ASO-PCR and MFC methods, respectively\textsuperscript{19}. Here we assessed the prognostic value of MRD detection by sequencing in a cohort of 133 MM patients enrolled in GEM (Grupo Español de Mieloma) Myeloma Trials as well as the concordance between MRD levels measured by MFC, ASO-PCR and high-throughput sequencing.
METHODS

Patients and clinical samples

Bone marrow samples from 133 patients included in GEM clinical trials were selected for inclusion in this study based on sample availability. Patients under 65 years were treated within the GEM2000 or GEM05<65 protocols, while elderly patients were treated within GEM05≥65 or GEM10≥65 trials. Detailed descriptions of these trials have been published. A previous analysis demonstrated that the achievement of negative MRD by MFC had prognostic value in young and elderly MM patients, and the prognostic influence of MRD assessment is independent of the type of treatment. All patients included in this study achieved at least very good partial response (VGPR) following front-line therapy. The samples for MRD investigation were obtained either after induction in the elderly population, and after induction plus ASCT in patients <65 years.

The studies were conducted in accordance with Declaration of Helsinki principles and were approved by the relevant Institutional Review Boards. Written informed consent was obtained from all subjects.

MRD measurements by high-throughput sequencing (HTS) method

HTS was carried out according to the LymphoSIGHT™ method (Sequenta, Inc.), as previously described. For MM diagnostic samples, genomic DNA was amplified using locus-specific primer sets for the immunoglobulin heavy chain locus (IGH) complete (IGH-VDJH), IGH incomplete (IGH-DJH), and immunoglobulin kappa locus (IGK). The amplified product was subjected to sequencing, and the sequences and frequencies of the different clonotypes in the sample were obtained. Myeloma gene rearrangements were identified using a method as
previously described.\textsuperscript{19,22} Patients in which a high-frequency myeloma clone (>5\%) was not identified were excluded from the MRD analysis. MRD was assessed in patients with a high-frequency myeloma clone using the $IGH-VDJ_H$ and $IGK$ or $IGH-VDJ_H$, $IGH-DJ_H$ and $IGK$ assays. Once the absolute amount of total cancer-derived molecules present in a sample was determined, a final MRD measurement was calculated, providing the number of cancer-derived molecules per 1 million cell equivalents.\textsuperscript{19} In cases where 2 or more tumor clones existed, the clone with the highest MRD value was reported. Molecular complete response was defined according to International Myeloma Working Group (IMWG) consensus recommendations.\textsuperscript{28}

\textit{MRD studies by flow cytometry and ASO-PCR methods}

BM samples were immunophenotyped using a 4-color direct immunofluorescence technique, as previously reported.\textsuperscript{10,17,29} The phenotypic aberrancies detected at diagnosis were used as patient-specific probes for MRD assessment after induction therapy. During follow-up, immunophenotypic response was defined as the absence of detectable MM plasma cells by MFC at a sensitivity level of $10^{-4}$ to $10^{-5}$, following the IMWG recommendations.\textsuperscript{28} In addition BM MRD were evaluated in a subset of patients by allele-specific oligonucleotide real-time quantitative PCR, using TaqMan technology as previously described.\textsuperscript{15,30}

\textit{Statistical analysis}

Statistical analyses were performed with the SPSS program (\textit{Statistical Package for Social Sciences Inc., Chicago, IL, USA}) for Windows version 21.0. Contingency tables were used to analyze associations between categorical variables, considering the $\chi^2$ test for statistical significance. T-test was used to compare averages of continuous variables between groups. A $P$
value less than 0.05 was considered significant. The concordance between sequencing, MFC and ASO-PCR was analyzed in log space using the Pearson coefficient test.

For survival analyses, the endpoints examined were time to tumor progression (TTP) and OS, both assessed according to the IMWG criteria from the start of treatment.\textsuperscript{28} For the univariate analysis, survival curves were calculated according to the Kaplan-Meier method and differences between curves were compared with the Wilcoxon test. A multivariate analysis was also performed using the Cox proportional regression hazard model to identify the factors that might have a significant independent influence on OS and TTP. The variables studied in the multivariate model are included in Table 1, together with molecular response determined by sequencing (negative/positive).
RESULTS

Identification of clonal rearrangements by deep sequencing

A clonal rearrangement was identified at a frequency higher than 5% in the diagnostic BM aspirate in 121 of 133 patients. The sequencing method successfully identified a myeloma clone that was suitable for follow-up MRD assessment in 91% of MM patients. Thus, the MRD applicability of deep sequencing was 91%.

The IGH-VDJ<sub>H</sub> assay was the most frequent gene rearrangement identified: at least one IGH-VDJ<sub>H</sub> clonal rearrangement was detected in 69% (84/121) of MM diagnostic samples, and at least one IGK clonal rearrangement was detected in 55% (66/121) of the samples. In contrast, the incomplete IGH-DJ<sub>H</sub> clonal rearrangement was identified in 48% (58/121).

Follow up samples were available for analysis in 110 out of 121 patients with a clonal rearrangement at diagnosis. During follow-up, most patients (n=80, 73%) remained positive by sequencing at MRD levels of 10<sup>-5</sup> or higher. Baseline clinical characteristics of patients grouped according to molecular remission status achieved by sequencing are summarized in Table 1.

Prognostic values of MRD assessment by sequencing

We evaluated the prognostic influence of MRD status by deep sequencing on TTP and OS (Table 2, Figure 1). Molecular response by deep sequencing, which corresponds to MRD negativity defined as MRD level <10<sup>-5</sup>, was associated with significantly longer TTP (median 80 vs. 31 months; P<0.0001) and OS (median not reached vs. 81 months, P=0.02). In the multivariate analysis for TTP, MRD negative status by deep sequencing was the single variable with statistical significance (HR 8.6, P=0.012). Only 8 patients with high risk cytogenetics were included in this cohort, and therefore cytogenetics risk-based subanalyses were not performed due to insufficient statistical power.
Subsequently, we evaluated the prognostic impact of different levels of MRD sensitivity defined by deep sequencing. Patients were grouped into 3 categories according to their MRD levels: i) $\geq 10^{-3}$ (n=43), ii) $10^{-3}$ to $10^{-5}$ (n=37) and iii) $<10^{-5}$ (n=30). The median TTP were: 27 months, 48 months, and 80 months, respectively ($P$ from 0.003 to 0.0001) (Figure 2A). No significant differences were observed in TTP of patients with MRD levels between $<10^{-3}$ and $>10^{-4}$ vs. $\leq 10^{-4}$ and $\geq 10^{-5}$. This sensitivity analysis was extended to assess OS across the 3 categories of MRD levels. Similar to the TTP analysis, MRD levels of $<10^{-5}$ were associated with significantly longer OS compared to patients with high MRD level (defined as $>10^{-3}$) (median not reached vs. 55 months, $P = 0.002$). Analogous results were found when comparing patients with MRD levels of $10^{-3}$ to $10^{-5}$ to patients with high MRD level ($>10^{-3}$) (median not reach vs. 55 months, $P = 0.02$) (Figure 2B).

We performed a sub-analysis to assess the importance of MRD by deep sequencing across different clinical trials. In this analysis, we studied young patients (n=76) and elderly patients (n=34) separately, and the prognostic significance of achieving MRD negativity by deep sequencing persisted (data not shown).

When limiting the study to the 62 patients in conventional CR at the time of analysis, 36 (58%) of 62 patients in CR were positive by sequencing at MRD levels at $10^{-5}$ and higher. With a median follow-up of 42 months, patients in CR who were MRD negative by deep sequencing had significantly longer TTP (median 131 vs. 35 months; $P=0.0009$) compared with patients in CR who were MRD positive by sequencing. Regarding OS, the medians were not reached in either of the two groups (Table 2, Figure 3).

All patients in VGPR were MRD positive by sequencing (92%), with four exceptions who were MRD negative by sequencing and positive by immunofixation. However, three of the
four patients became immunofixation negative shortly thereafter, based on follow-up evaluations.

Correlation between MFC, ASO-PCR and sequencing results

MRD information by MFC and ASO-PCR analysis was available in 99 and 41 patients, respectively. The prognostic significance of MRD status determined by these techniques is summarized in Table 2.

Upon comparing the MRD results obtained by MFC and ASO-PCR with sequencing results, a good degree of concordance was observed across the three platforms. When comparing MFC vs. sequencing, 83% of the samples yielded concordant results: 60 (61%) were MRD-positive and 22 (22%) were MRD-negative by both methods, with an $r^2$ of 0.58. For the comparison between ASO-PCR and sequencing the concordance was 85%: 20 (49%) were MRD-positive and 15 (36%) were MRD-negative by both methods, with an $r^2$ of 0.54 for the comparison of quantitative MRD levels.

To assess the clinical significance of discrepancies between platforms, we focused on the 99 patients in which we had MRD results using both sequencing and MFC. As mentioned above, 82 cases had concordant results (60 double positives and 22 double negatives) while 12 patients were negative by MFC but still remained positive by sequencing (MFC-/sequencing+); the 5 remaining patients had the opposite pattern (MCF+/sequencing-). The prognosis of sequencing-cases (median TTP not reached) was significantly better than MFC+/sequencing+ samples (median TTP 29 months, $P=0.0001$). Importantly, patients who were MFC-/sequencing+ had an intermediate TTP (median 50 months, $P=0.05$ for the comparison with sequencing- cases). Of the five cases with MFC+/sequencing-, only one patient has progressed so far.
DISCUSSION

Over the last decade, there has been enormous progress in the treatment of MM. With the introduction of novel agents such as immunomodulatory drugs (thalidomide/lenalidomide/pomalidomide) and proteasome inhibitors (bortezomib, carfilzomib) a CR can now be achieved in a significant fraction of newly diagnosed MM patients, something which was unimaginable ten years ago. Consequently, the use of more sensitive assays for detecting and monitoring clinically meaningful residual disease has become a relevant tool for assessing treatment efficacy and prognostication. MRD measurements can be used to predict OS and PFS, to inform consolidation and maintenance strategies, and to evaluate the comparative efficacy of novel therapies.

Recent studies have shown that MFC, a sensitive method for detection of residual myeloma cells, is predictive of PFS and OS in MM patients. Moreover, MFC remission was shown to have prognostic value in patients in CR assessed by traditional immunofixation response criteria, which indicates that the deeper the response, the longer the survival. These studies have been replicated in larger cohorts and have contributed to the recent proposal by the IMWG to create a new response category, “immunophenotypic CR”, which is defined as the absence of phenotypically aberrant plasma cells in BM analyzed by MFC. These reports underscore the emerging importance of MRD assessment in MM patients and suggest that novel methods for MRD detection can play a role in the evolving MM treatment paradigm.

Similarly, ASO-PCR provides an accurate quantification of residual disease. Several recent reports using quantitative PCR have shown the ability to stratify MM patient cohorts in the transplant setting with different prognoses. Thus, the term “molecular response” has also been included in the IMWG criteria and is considered the highest degree of response. However, most patients who achieve an MRD negative status eventually relapse, which indicates
that the sensitivity and specificity of traditional techniques for MRD assessment can be improved.

In this study, we tested whether measurement of residual myeloma cells using the LymphoSIGHT™ sequencing platform provides a sensitive alternative to other MRD methods. The sequencing-based method uses consensus primers to universally amplify and sequence all rearranged immunoglobulin gene segments present in a myeloma clone. This method assesses stable and specific DNA tumor markers, providing a direct, sensitive and objective quantification of myeloma disease burden. In this study, the high-throughput sequencing approach identified a tumor marker in 91% of MM patients, and thus was “applicable” to more than 90% of MM patients. Applicability is a critical factor in the evaluation of any MRD assessment technique, as a higher rate of applicability directly translates into more patients that can benefit from MRD investigations. In this study, applicability was based on the identification of a high-frequency (>5%) tumor sequence in the baseline BM aspirate that was suitable for analysis in follow-up samples. The sequencing method provides a significant improvement in applicability compared to ASO-PCR, which has an applicability rate typically below 70%30,41,42, and avoids the necessity of designing individualized PCR probes. Only MFC has demonstrated a higher applicability (virtually 100% of patients with new MFC methods)17; however, the sensitivity of MFC (10⁻⁴-10⁻⁵) is one to two logs lower than that achieved by the high-throughput sequencing method (10⁻⁶)19. The sequencing method can detect a single cell and is limited only by input cell amount. Most of the samples analyzed by sequencing in this study had fewer than 300,000 input cells. Therefore, although the sequencing platform has the sensitivity to detect 1 in 1 million cells, the sequencing MRD positivity threshold for this study was set at 1 in 100,000 cells. Although sensitivities higher than 10⁻⁴ to 10⁻⁵ can be reached with the new MFC instruments, they will require
analysis of up to $2 \times 10^6$ cells through an accurate measurement that has not been systematically evaluated to date.

We analyzed the prognostic value of different levels of MRD assessment by deep sequencing. The sequencing platform identified 3 groups of patients with different TTP: patients with high ($>10^{-3}$), intermediate ($10^{-3}$ to $10^{-5}$) and low MRD levels ($<10^{-5}$) showed significantly different TTP: 27, 48 and 80 months, respectively, which indicates that deeper responses were associated with significantly longer survival. The possibility of stratifying patients into three risk categories by deep sequencing (low, intermediate and high) could be a significant advantage over less sensitive techniques such as Fluorescence-PCR (sensitivity around $10^{-3}$) that can only identify a subgroup of high risk patients.\textsuperscript{13}

When analyzing the correlation between MRD and conventional response status, the vast majority of patients in VGPR (92\%) were MRD positive, and, although this would seem obvious, this is the first empirical data to establish this correlation. When limiting the analysis to patients in CR, MRD levels at or below $10^{-5}$ by sequencing stratified the patients into 2 groups with significantly different TTP. Specifically, there was significantly improved TTP in the MRD negative group versus the MRD positive group among the CR patients (median 131 vs. 35 months; $P=0.0009$).

A high level of concordance was observed between MRD levels by deep sequencing and results obtained by MFC or ASO-PCR. All three platforms discriminated between MRD positive high-risk patients and MRD negative cases which exhibited a favorable prognosis (Table 2). However, patients that were MRD negative by sequencing showed increased TTP compared to those that were sequencing positive/MFC negative ($P=0.05$). This analysis was performed using a threshold of $10^{-5}$ for defining detectable disease by MFC. These results support the
interpretation that the low level MRD detected by the higher sensitivity of the sequencing platform compared to MFC is clinically significant.

It is important to note that the sensitivity of all three approaches is limited by the amount and purity of DNA or the number of cells analyzed, a critical factor that depends on the specimen characteristics. As a result, the sensitivity will improve if more BM material is obtained for analysis. Indeed, many of the cases in this study were evaluated by MFC by analyzing up to 2x10^6 cells, which translated into an improvement in MFC results (data not shown). Finally, molecular approaches utilize a stable DNA marker and employ a reproducible universal assay with digital readout, which avoids the problems of MFC lab-to-lab variability. Therefore, the sequencing method has the potential to be distributed across multiple labs, as it relies on automated data analysis and does not involve expert interpretation by an operator.

Other challenges associated with the MFC platform are related to sample requirements. As opposed to the MFC platform which requires live cells, the sequencing-based approach utilizes a stable DNA marker and can be performed on fresh samples, as well as stored cells and DNA, facilitating retrospective analysis and flexible sample collection requirements and transfer in clinical settings. In turn immunophenotyping has the advantage of speed with results available in a couple of hours.

However, the use of BM samples for MRD assessment presents a potential challenge for all MRD methods. The pattern of BM infiltration in MM is not uniform, which is an important distinction from other hematological disorders, such as the acute leukemias. This, together with extramedullary disease, represents a potential pitfall common to all MRD techniques that utilize BM samples, as non-representative samples of disease infiltration are occasionally obtained. For this reason, while MRD positive results are consistently informative, negative results may correspond to a false negative case. The use of alternative methods for disease assessment such
as imaging techniques (positron emission tomography-computed tomography)\textsuperscript{47}, monitoring of clonogenic MM progenitors\textsuperscript{48,49} or MM circulating tumor cells\textsuperscript{22,5049}, could provide complementary information to MRD and improve the estimation of risk of progression.

This study suggests that MRD assessment by sequencing is a useful method for patient risk stratification, and the definition of molecular CR in clinical trials can be extended to include the sequencing method. Indeed, achievement of MRD negativity may ultimately serve as a primary endpoint in clinical trials for MM. In addition, sensitive methods of MRD detection may contribute to the design of patient-specific treatment approaches, such as de-escalation of therapy for MRD negative patients or continuous or escalation of treatment for MRD positive patients, which is consistent with the current standard of care in other hematologic malignancies. In summary, this data underscores the promise of sequencing-based MRD assessment in MM patients and provides strong rationale for utilization of improved MRD assessment in the evolving MM clinical paradigm.
ACKNOWLEDGMENTS

This research project was supported by grants, PS09/01370, PS09/1450, PI12/01761 and PI12/023121 from the Fondo de Investigaciones Sanitarias (FIS), RD12/10 Red de Cáncer (Cancer Network of Excellence) from the Instituto de Salud Carlos III, Spain and from the Fondo de Investigaciones Sanitarias (FIS), Asociación Española Contra el Cáncer (AECC; GCB120981SAN) and CRIS foundation. This study was supported in part by research funding from Sequenta, Inc. to F.P., L.W., M.M., and M.F.

AUTHORSHIP CONTRIBUTIONS


CONFLICT OF INTEREST DISCLOSURE

F.P., L.W., M.M., and M.F. are employees of and holders of equity in Sequenta, Inc.
REFERENCES


25. Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and
dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a

alternating administration of bortezomib, melphalan and prednisone and lenalidomide plus
dexamethasone in elderly patients with newly diagnosed multiple myeloma patients:

by multiparameter flow cytometry in 516 myeloma patients included in three consecutive

uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus

residual disease by multiparameter flow cytometry predict unsustained complete response after

in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time
quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90(10):1365-
1372.

2012;9(3):135-143.


### TABLES

**Table 1. Main patient characteristics at diagnosis grouped according to molecular response by deep sequencing**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Non-MR (n = 80)</th>
<th>MR (n = 30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male / female, %</td>
<td>51/49</td>
<td>52/48</td>
</tr>
<tr>
<td>Mean age, years (range)</td>
<td>62(39-84)</td>
<td>61(42-75)</td>
</tr>
<tr>
<td>Mean β2-microglobulin, mg/L</td>
<td>4.2</td>
<td>4.3</td>
</tr>
<tr>
<td>Mean hemoglobin, mg/dL</td>
<td>11.2</td>
<td>11</td>
</tr>
<tr>
<td>Mean creatinine, mg/dL</td>
<td>1</td>
<td>1.1</td>
</tr>
<tr>
<td>Mean serum calcium, mg/dL</td>
<td>9.5</td>
<td>9.8</td>
</tr>
<tr>
<td>Mean albumin, g/dL</td>
<td>3.7</td>
<td>3.4</td>
</tr>
<tr>
<td>LDH high, %</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Durie-Samon Stage (I/II/III), %</td>
<td>10/48/42</td>
<td>4/36/60</td>
</tr>
<tr>
<td>Durie-Salmon Stage A/B, %</td>
<td>98/2</td>
<td>96/4</td>
</tr>
<tr>
<td>ISS I/II/III, %</td>
<td>49/39/12</td>
<td>77/23/0</td>
</tr>
<tr>
<td>Bone Lesions (non lesion, minor lesions, major lesions) (%)</td>
<td>26/42/32</td>
<td>33/30/37</td>
</tr>
<tr>
<td>Maximum response after front-line therapy*, n</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete remission (CR)</td>
<td>36*</td>
<td>26*</td>
</tr>
<tr>
<td>Very good partial remission (VGPR)</td>
<td>42*</td>
<td>4*</td>
</tr>
</tbody>
</table>

* Pval(Chi-square) <0.001
### Table 2. Survival values according to conventional responses and for different levels of minimal residual disease determined by deep sequencing, multiparametric flow cytometry or ASO-PCR

<table>
<thead>
<tr>
<th>All Series</th>
<th>Time to Progression</th>
<th>Overall Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>5y, %</td>
</tr>
<tr>
<td>SEQ &lt; 10^{-5}</td>
<td>30</td>
<td>84</td>
</tr>
<tr>
<td>SEQ &gt; 10^{-5}</td>
<td>80</td>
<td>29</td>
</tr>
<tr>
<td>MFC &lt; 10^{-5}</td>
<td>34</td>
<td>66</td>
</tr>
<tr>
<td>MFC &gt; 10^{-5}</td>
<td>65</td>
<td>32</td>
</tr>
<tr>
<td>ASO-PCR &lt; 10^{-5}</td>
<td>22</td>
<td>65</td>
</tr>
<tr>
<td>ASO-PCR &gt; 10^{-5}</td>
<td>19</td>
<td>0</td>
</tr>
</tbody>
</table>

**Conventional Response and MRD**

|            | N       | 5y, %     | median mo (±95% CI) | HR  | P-value |
|------------|---------------------|------------|
| VGPR       | 48     | 31        | 29 (18-40)         | 2.00 | .001    |
| CR         | 62     | 49        | 60 (39-80)         | 2.17 | .022    |
| CR & SEQ < 10^{-5} | 26    | 82        | 131 (51-154)       | 2.87 | .001    |
| CR & SEQ > 10^{-5} | 36    | 31        | 35 (30-41)         | -    | .172    |
| CR & MFC < 10^{-5} | 28    | 65        | NR                  | 2.87 | .06    |
| CR & MFC > 10^{-5} | 33    | 37        | 35(30-41)           | -    | .596    |

**Abbreviations:** VGPR: very good partial Response, CR: Complete Response, MRD: minimal residual disease, SEQ: minimal residual disease by deep sequencing, MFC: minimal residual disease by multiparametric flow cytometry, ASO-PCR: minimal residual disease by allele specific polymerase chain reaction
FIGURE LEGENDS

**Figure 1.** Time to Progression (A) and Overall Survival (B) of the series according to minimal residual disease (MRD) levels ($\leq 10^{-5}$ vs. $>10^{-5}$) as determined by deep sequencing.

**Figure 2.** A) Time to Progression of the series stratified according to different minimal residual disease (MRD) levels (>10$^{-3}$ vs. 10$^{-3}$ to 10$^{-5}$ vs. <10$^{-5}$) as determined by deep sequencing. B) Overall Survival of the series stratified according to different minimal residual disease (MRD) levels (>10$^{-3}$ vs. 10$^{-3}$ to 10$^{-5}$ vs. <10$^{-5}$) as determined by deep sequencing.

**Figure 3.** Time to Progression for patients achieving conventional Complete Remission (CR), according to minimal residual disease (MRD) status as determined by deep sequencing.
Figure 1

A

Time to Progression, %

- MRD-, n = 30
- MRD+, n = 80

threshold: $10^{-5}$

$P < 0.0001$

B

Survival, %

$P = 0.02$
Figure 2
Figure 3
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Joaquin Martinez-Lopez, Juan J. Lahuerta, François Pepin, Marcos González, Santiago Barrio, Rosa Ayala, Noemi Puig, María A. Montalban, Bruno Paiva, Li Weng, Cristina Jiménez, Maria Sopena, Martin Moorhead, Teresa Cedena, Immaculada Rapado, María Victoria Mateos, Laura Rosiñol, Albert Oriol, María J. Blanchard, Rafael Martinez, Joan Bladé, Jesús San Miguel, Malek Faham and Ramón García-Sanz

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.